STAT+: Congressional lawmakers urge FTC to investigate insulin makers over their pricing
In the latest flare up over the cost of insulin, several Congressional lawmakers want the Federal Trade Commission to investigate the three big manufacturers of the diabetes treatment for “exploiting” their market power and repeatedly raising prices.
The lawmakers, who are all Democrats, cited instances in which the companies — Eli Lilly (LLY), Novo Nordisk (NVO), and Sanofi (SNY) — raised prices nearly simultaneously. As an example, two of the insulin makers increased prices by 16% within a day of each other. In fact, there were at least 13 such cases involving Sanofi and Novo Nordisk between 2009 and 2019, and Lilly often followed suit, they claimed.
